Last updated on 9-1-2025 by Sigrid De Keersmaecker
Auteurs
Annefleur D.O. Hensen; Maria J.G.T. Vehreschild; Dale N. Gerding; Oleg Krut; Chen, Wilbur; Vincent B. Young; Tzipori, Saul; Solbach, Philipp; Gibani, Malick Mahdi; Christopher Chiu; Sigrid C. J. De Keersmaecker; Dasyam, Dileep; Morel, Sandra; Devaster, Jeanne-Marie; Corti, Nicoletta; Ed J. Kuijper; Roestenberg, Meta; Smits, Wiep KlaasTrefwoorden
Samenvatting:
Background: Clostridioides difficile (C. difficile) remains the leading cause of healthcare-associated diarrhoea, posing treatment challenges due to antibiotic resistance and high relapse rates. Fecal microbiota transplantation (FMT) is a novel treatment strategy to prevent relapses of C. difficile infection (CDI), however the exact components conferring colonisation resistance are unknown, hampering its translation to a medicinal product. Development of novel products independent of antibiotics, which increase colonisation resistance or induce protective immune mechanisms are urgently need…